FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667039> ?p ?o ?g. }

• W4385667039 endingPage "e0917658" @default.
• W4385667039 startingPage "e0917658" @default.
• W4385667039 abstract "Topic: 22. Stem cell transplantation - Clinical Background: Despite novel biologic agents, steroid-dependent or -refractory acute graft-versus-host disease (aGVHD) remains a severe complication of allogeneic hematopoietic cell transplantation (alloHCT). Aims: Based on our long-lasting experience with extracorporeal photopheresis (ECP), we aimed to prospectively assess the role of ECP as early second-line treatment in steroid-dependent and refractory aGVHD. Methods: We enrolled consecutive patients with steroid-dependent or refractory grade (gr) II-IV aGVHD post alloHCT over the last decade (January 2013 - December 2022). All patients with unrelated or haploidentical donors received thymoglobulin (ATG) 5mg/kg as prophylaxis. Post-transplant GVHD prophylaxis included cyclosporine – methotrexate in myeloablative and cyclosporine – mycophenolate mofetil in reduced toxicity or intensity regimens. ECP was commenced after assessment of response to 5 days of steroid treatment according to our protocol: 2 sessions/week for 1 month, 1 session/2 weeks for 3 months, evaluation of response and 1 session/month for 6 months. Before ruxolitinib’s availability, ATG was commenced simultaneously with ECP initiation in steroid-refractory patients. Results: We studied 28 patients, aged 45 (18-67), post alloHCT with myeloablative (16), reduced toxicity (8) and intensity (4) conditioning, from sibling (4), matched (11) or one locus mismatched (12) volunteer unrelated and haploidentical (1) donors. Disease risk index was very high (1), high (11), intermediate (14) and low (2). Acute GVHD was observed at day +17 (8-50). Skin, intestine and liver involvement was evident in 9 patients, skin and intestine in 13 and skin only in 6 patients. Thirteen patients were steroid-dependent and 15 steroid-refractory. ECP was commenced at day +18 (8-56) for 15 (4-20) sessions. The majority of patients (19/27) presented partial (7), very good (11) or complete (1) response to ECP. With 9.9 (1.7-113) months of follow-up, immunosuppression was reduced in 12/27 and ceased in 1 patient. Clinically significant bacterial infections were found in 19 patients, fungal in 3, CMV and EBV reactivation in 19 and 12 respectively and other viral in 6 patients. Cumulative incidence (CI) of chronic GVHD was 56.4 at 1-year.Five-year overall survival (OS) was 34%. Reduction of immunosuppression (p=0.026) and number of ECP sessions (p<0.001) were associated with improved OS, irrespectively of other factors. In particular, optimal OS was observed in patients that received more than 19 ECP sessions (Figure). Summary/Conclusion: Our data confirm that ECP should be considered early in the course of steroid-dependent or refractory aGVHD, even in the era of novel biologic agents. Optimal timing of intervention, frequency, duration and tapering schedule of ECP remain important unanswered questions.Keywords: Allogeneic, Graft-versus-host disease (GVHD), Hematopoietic cell transplantation, Extracorporeal photopheresis" @default.
• W4385667039 created "2023-08-09" @default.
• W4385667039 creator A5002560472 @default.
• W4385667039 creator A5003133664 @default.
• W4385667039 creator A5003906508 @default.
• W4385667039 creator A5007210918 @default.
• W4385667039 creator A5011406652 @default.
• W4385667039 creator A5018221472 @default.
• W4385667039 creator A5045576894 @default.
• W4385667039 creator A5051463822 @default.
• W4385667039 creator A5051943477 @default.
• W4385667039 creator A5056615293 @default.
• W4385667039 creator A5060045729 @default.
• W4385667039 creator A5061193434 @default.
• W4385667039 creator A5083412701 @default.
• W4385667039 creator A5086754307 @default.
• W4385667039 creator A5089992014 @default.
• W4385667039 creator A5092614006 @default.
• W4385667039 date "2023-08-01" @default.
• W4385667039 modified "2023-10-17" @default.
• W4385667039 title "P1311: LONG-TERM SAFETY AND EFFICACY OF EXTRACORPOREAL PHOTOPHERESIS AS EARLY SECOND-LINE TREATMENT FOR PATIENTS WITH STEROID-DEPENDENT OR REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE." @default.
• W4385667039 doi "https://doi.org/10.1097/01.hs9.0000972132.09176.58" @default.
• W4385667039 hasPublicationYear "2023" @default.
• W4385667039 type Work @default.
• W4385667039 citedByCount "0" @default.
• W4385667039 crossrefType "journal-article" @default.
• W4385667039 hasAuthorship W4385667039A5002560472 @default.
• W4385667039 hasAuthorship W4385667039A5003133664 @default.
• W4385667039 hasAuthorship W4385667039A5003906508 @default.
• W4385667039 hasAuthorship W4385667039A5007210918 @default.
• W4385667039 hasAuthorship W4385667039A5011406652 @default.
• W4385667039 hasAuthorship W4385667039A5018221472 @default.
• W4385667039 hasAuthorship W4385667039A5045576894 @default.
• W4385667039 hasAuthorship W4385667039A5051463822 @default.
• W4385667039 hasAuthorship W4385667039A5051943477 @default.
• W4385667039 hasAuthorship W4385667039A5056615293 @default.
• W4385667039 hasAuthorship W4385667039A5060045729 @default.
• W4385667039 hasAuthorship W4385667039A5061193434 @default.
• W4385667039 hasAuthorship W4385667039A5083412701 @default.
• W4385667039 hasAuthorship W4385667039A5086754307 @default.
• W4385667039 hasAuthorship W4385667039A5089992014 @default.
• W4385667039 hasAuthorship W4385667039A5092614006 @default.
• W4385667039 hasBestOaLocation W43856670391 @default.
• W4385667039 hasConcept C121332964 @default.
• W4385667039 hasConcept C126322002 @default.
• W4385667039 hasConcept C141071460 @default.
• W4385667039 hasConcept C142424586 @default.
• W4385667039 hasConcept C2777408962 @default.
• W4385667039 hasConcept C2777630719 @default.
• W4385667039 hasConcept C2779972918 @default.
• W4385667039 hasConcept C2781059491 @default.
• W4385667039 hasConcept C2909675724 @default.
• W4385667039 hasConcept C2909962264 @default.
• W4385667039 hasConcept C2911091166 @default.
• W4385667039 hasConcept C71924100 @default.
• W4385667039 hasConcept C87355193 @default.
• W4385667039 hasConcept C90924648 @default.
• W4385667039 hasConceptScore W4385667039C121332964 @default.
• W4385667039 hasConceptScore W4385667039C126322002 @default.
• W4385667039 hasConceptScore W4385667039C141071460 @default.
• W4385667039 hasConceptScore W4385667039C142424586 @default.
• W4385667039 hasConceptScore W4385667039C2777408962 @default.
• W4385667039 hasConceptScore W4385667039C2777630719 @default.
• W4385667039 hasConceptScore W4385667039C2779972918 @default.
• W4385667039 hasConceptScore W4385667039C2781059491 @default.
• W4385667039 hasConceptScore W4385667039C2909675724 @default.
• W4385667039 hasConceptScore W4385667039C2909962264 @default.
• W4385667039 hasConceptScore W4385667039C2911091166 @default.
• W4385667039 hasConceptScore W4385667039C71924100 @default.
• W4385667039 hasConceptScore W4385667039C87355193 @default.
• W4385667039 hasConceptScore W4385667039C90924648 @default.
• W4385667039 hasIssue "S3" @default.
• W4385667039 hasLocation W43856670391 @default.
• W4385667039 hasLocation W43856670392 @default.
• W4385667039 hasOpenAccess W4385667039 @default.
• W4385667039 hasPrimaryLocation W43856670391 @default.
• W4385667039 hasRelatedWork W1990778815 @default.
• W4385667039 hasRelatedWork W2022940423 @default.
• W4385667039 hasRelatedWork W2091592676 @default.
• W4385667039 hasRelatedWork W2144192117 @default.
• W4385667039 hasRelatedWork W2589053015 @default.
• W4385667039 hasRelatedWork W2884628875 @default.
• W4385667039 hasRelatedWork W2911103373 @default.
• W4385667039 hasRelatedWork W2960029929 @default.
• W4385667039 hasRelatedWork W2983105338 @default.
• W4385667039 hasRelatedWork W4312181414 @default.
• W4385667039 hasVolume "7" @default.
• W4385667039 isParatext "false" @default.
• W4385667039 isRetracted "false" @default.
• W4385667039 workType "article" @default.